We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Menopause
MedXY News
EnglishTag

Menopause

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating Voice Disorder Risks in Peri- and Post-Menopausal Women Using Hormone Replacement Therapy: Insights from a Large TriNetX Cohort
newsMenopausedysphonia

Evaluating Voice Disorder Risks in Peri- and Post-Menopausal Women Using Hormone Replacement Therapy: Insights from a Large TriNetX Cohort

By MedXY|Sep 7, 2026

This study investigates the association between peri- and post-menopausal hormone replacement therapy (HRT) and the risk of voice disorders, revealing transiently increased dysphonia risk within the first nine months but no sustained clinic

Menopausal Transition and Thyroid Function: Deciphering the Impact Beyond Aging in Midlife Women
Diabetes & EndocrinologyfT4
Nghiên cứu dọc theo thời gian

Menopausal Transition and Thyroid Function: Deciphering the Impact Beyond Aging in Midlife Women

By MedXY|Aug 21, 2026

A comprehensive longitudinal study reveals that menopausal transition does not significantly alter thyroid function beyond normal aging effects in healthy women, clarifying the interplay between menopause and thyroid health.

Menopause Management in Patients with Cancer: A Symptom‑Based, Risk‑Stratified Framework
newsgenitourinary syndromehot flashes

Menopause Management in Patients with Cancer: A Symptom‑Based, Risk‑Stratified Framework

By MedXY|Aug 12, 2026

Practical, symptom‑focused recommendations for managing menopause in people with cancer—balancing symptom relief with oncologic safety using nonhormonal first-line strategies, selective use of local estrogen, and shared decision making for

Integrative Medicine Approaches for Menopause: Evidence-Based Nonhormonal Strategies for Symptom Management
newsintegrative medicinenonhormonal therapy

Integrative Medicine Approaches for Menopause: Evidence-Based Nonhormonal Strategies for Symptom Management

By MedXY|Aug 18, 2026

This article reviews evidence-based integrative medicine approaches for menopause, including lifestyle, mind-body therapies, nutrition, botanicals, and acupuncture, emphasizing nonhormonal options for symptom relief and health optimization.

Can Postmenopausal Women Still Have a Sex Life? Stop Worrying About Weekly Frequency—Comfort, Safety, and Mutual Desire Matter Most
Intimate HealthMenopause

Can Postmenopausal Women Still Have a Sex Life? Stop Worrying About Weekly Frequency—Comfort, Safety, and Mutual Desire Matter Most

By MedXY|Aug 7, 2026

Menopause isn't a "stop button" for intimacy, nor is there any medical rule dictating that you must retire your sex life at a certain age. What truly

Disparities and Persistence in Systemic Hormone Therapy Among Menopausal Women: Insights from a Large Real-World Analysis
newsracial disparitiesMenopause

Disparities and Persistence in Systemic Hormone Therapy Among Menopausal Women: Insights from a Large Real-World Analysis

By MedXY|Aug 18, 2026

A comprehensive study reveals initiation rates, duration, and racial disparities in systemic hormone therapy use among menopausal women, emphasizing critical care gaps and the need for equitable interventions.

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors
newslong-term outcomesMenopause

Safety and Long-Term Benefits of Hormone Therapy After Chemoradiation in Young Cervical Cancer Survivors

By MedXY|Aug 18, 2026

Hormone therapy initiated within one year after chemoradiotherapy in young patients with locally advanced cervical cancer is associated with reduced metabolic, skeletal, and cerebrovascular risks, and improved survival without increased onc

Fibroids Do Not Uniformly Regress After Menopause: Reframing Leiomyoma Care Across the Menopausal Transition
newsChảy máu tử cung bất thườnguterine leiomyomas

Fibroids Do Not Uniformly Regress After Menopause: Reframing Leiomyoma Care Across the Menopausal Transition

By MedXY|Aug 18, 2026

A contemporary review shows that uterine leiomyomas often persist across menopause, requiring symptom-driven evaluation, structured imaging, and individualized management rather than assumptions of spontaneous regression.

Postmarketing Data Link Fezolinetant Primarily to Early Transaminase Elevations Rather Than Overt Liver Injury
GastroenterologyfezolinetantFAERS

Postmarketing Data Link Fezolinetant Primarily to Early Transaminase Elevations Rather Than Overt Liver Injury

By MedXY|Aug 18, 2026

FAERS postmarketing data suggest fezolinetant is associated with an early hepatic adverse event reporting signal, driven mainly by liver enzyme elevations rather than consistent severe clinical liver injury.

Menopausal Hot Flushes and Night Sweats May Be Linked to Retirement: What an Australian Study Found
OB/GYN & Women's Healthhot flushesnight sweats

Menopausal Hot Flushes and Night Sweats May Be Linked to Retirement: What an Australian Study Found

By MedXY|Aug 18, 2026

A large Australian longitudinal study found that women with both hot flushes and night sweats had slightly higher odds of retirement, suggesting menopausal symptom burden may influence workforce participation.

Earlier Menopause Linked to Accelerated Multimorbidity Progression: UK Biobank Multi-State Analysis Reveals Critical Windows for Preventive Intervention
newschronic diseaseMenopause

Earlier Menopause Linked to Accelerated Multimorbidity Progression: UK Biobank Multi-State Analysis Reveals Critical Windows for Preventive Intervention

By MedXY|Apr 6, 2026

A large UK Biobank cohort study of 121,017 postmenopausal women reveals that earlier menopause significantly increases risks of multimorbidity progression, with women experiencing premature menopause facing 32% higher risk of developing fir

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety
Diabetes & Endocrinologycardiovascular diseaseHypothyroidism

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

By MedXY|Mar 12, 2026

A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk
newsMenopauseoncology

Beyond the Incessant Ovulation Hypothesis: How Menopausal Status and Birth Cohort Reshape Ovarian Cancer Risk

By MedXY|Feb 6, 2026

A massive cohort study of 2.2 million women reveals that ovarian cancer risk factors vary significantly by menopausal status and birth year. While early menarche and low parity remain universal risks, the protective benefits of breastfeedin

Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks
Cardiologycardiovascular riskhormone therapy

Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks

By MedXY|Dec 16, 2025

Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Clinical UpdatesElinzanetantMenopause

Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management

By MedXY|Nov 13, 2025

Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
newsElinzanetantMenopause

Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile

By MedXY|Nov 13, 2025

OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean diff

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes
OB/GYN & Women's HealthElinzanetantMenopause

FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes

By MedXY|Oct 24, 2025

Bayer’s Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable

Menopause and Multiple Sclerosis: Evaluating the Impact on Disability Progression
Allergy & Immunologydisability progressionMenopause

Menopause and Multiple Sclerosis: Evaluating the Impact on Disability Progression

By MedXY|Oct 6, 2025

A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging’s role in disease trajec

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review
Clinical Updatesbreast cancercognitive decline

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY|Oct 6, 2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone thera

Estradiol Hormone Therapy Route Influences Memory Types in Postmenopausal Women
Clinical Updatescognitive performanceestradiol

Estradiol Hormone Therapy Route Influences Memory Types in Postmenopausal Women

By MedXY|Oct 6, 2025

Estradiol-based hormone therapy’s impact on memory varies by administration route—with transdermal delivery linked to better episodic memory and oral delivery to improved prospective memory. Earlier menopause onset correlates with poo

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities